Latuda approved for schizophrenia

The FDA has approved Latuda (lurasidone HCl tablets, from Sunovion), an oral once-daily atypical antipsychotic, for the treatment of schizophrenia in adults. This approval was based on four six-week controlled studies which demonstrated that Latuda (lurasidone HCl tablets) has significantly greater improvement compared to placebo on the primary efficacy measures [the Positive and Negative Syndrome Scale (PANSS) total score and the Brief Psychiatric Rating Scale-derived from PANSS (BPRSd)] at study endpoint.

Latuda is expected to be available during the first quarter of 2011 in 40mg and 80mg dosage strengths.

For more information call (888) 394-7377 or visit www.sunovion.com.